Cite
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
MLA
Ziemssen, Tjalf, et al. “Safety and in Vivo Immune Assessment of Escalating Doses of Oral Laquinimod in Patients with RRMS.” Journal of Neuroinflammation, vol. 14, no. 1, Aug. 2017, p. 172. EBSCOhost, https://doi.org/10.1186/s12974-017-0945-z.
APA
Ziemssen, T., Tumani, H., Sehr, T., Thomas, K., Paul, F., Richter, N., Samara, E., Spiegelstein, O., Sorani, E., Bar-Ilan, O., Mimrod, D., & Hayardeny, L. (2017). Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. Journal of Neuroinflammation, 14(1), 172. https://doi.org/10.1186/s12974-017-0945-z
Chicago
Ziemssen, Tjalf, Hayrettin Tumani, Tony Sehr, Katja Thomas, Friedemann Paul, Nils Richter, Emil Samara, et al. 2017. “Safety and in Vivo Immune Assessment of Escalating Doses of Oral Laquinimod in Patients with RRMS.” Journal of Neuroinflammation 14 (1): 172. doi:10.1186/s12974-017-0945-z.